| Autor: |
Beketova, Elena, Owens, Jake L., Asberry, Andrew M., Hu, Chang-Deng |
| Zdroj: |
Cancer Gene Therapy; March 2022, Vol. 29 Issue: 3-4 p264-276, 13p |
| Abstrakt: |
Protein arginine methyltransferase 5 (PRMT5) was discovered two decades ago. The first decade focused on the biochemical characterization of PRMT5 as a regulator of many cellular processes in a healthy organism. However, over the past decade, evidence has accumulated to suggest that PRMT5 may function as an oncogene in multiple cancers via both epigenetic and non-epigenetic mechanisms. In this review, we focus on recent progress made in prostate cancer, including the role of PRMT5 in the androgen receptor (AR) expression and signaling and DNA damage response, particularly DNA double-strand break repair. We also discuss how PRMT5-interacting proteins that are considered PRMT5 cofactors may cooperate with PRMT5 to regulate PRMT5 activity and target gene expression, and how PRMT5 can interact with other epigenetic regulators implicated in prostate cancer development and progression. Finally, we suggest that targeting PRMT5 may be employed to develop multiple therapeutic approaches to enhance the treatment of prostate cancer. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink